LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Identifies Genetic Mutation Responsible for CSID

By LabMedica International staff writers
Posted on 16 Dec 2014
Image: The ABI 96-capillary 3730xl DNA Analyzer (Photo courtesy of Life Technologies).
Image: The ABI 96-capillary 3730xl DNA Analyzer (Photo courtesy of Life Technologies).
A common mutation for congenital sucrose-isomaltase deficiency has been identified in the Inuit population where the condition is highly prevalent.

Congenital sucrose-isomaltase deficiency (CSID) is a rare hereditary cause of chronic diarrhea in children and people with this condition lack the intestinal brush-border enzyme required for digestion of di- and oligosaccharides, including sucrose and isomaltose, leading to malabsorption.

Scientists at the University of Ottawa (Canada) and their colleagues isolated DNA from the blood of a child from Baffin Island in Nunavut, Canada's largest territory, in whom severe chronic diarrhea developed while taking sucrose-containing infant formula. They then sequenced the sucrose-isomaltase (SI) gene in this child to identify the specific genetic mutation responsible for the disorder.

The team then genotyped and sequenced 128 anonymized samples from Inuit controls from a range of Canadian Arctic locales on an ABI 3730 DNA Analyzer (Applied Biosystems; Foster City, CA, USA). Sequencing of the SI gene identified a novel homozygous frameshift mutation in the proband NM_001041.3:c.273_274delAG (p.Gly92Leufs*8). From the 128 anonymized samples from Inuit controls they identified a further two homozygous and 40 heterozygous individuals. The observed allele frequency of this mutation in the sample was 17.2% (44 of 256 total alleles).

Matthew A. Lines, MD, the senior author of the study, said, “People with CSID may remain asymptomatic unless they consume sucrose, which is why persons consuming a Western diet are more likely to become ill. Timely recognition of this condition and initiation of appropriate therapy is paramount. Our study should prompt physicians to consider CSID and to review the sucrose content of a patient's diet, and specifically that of infant formula if applicable”. Dr. Lines added that as result of the team's findings CSID, which formerly required an intestinal biopsy for diagnosis, can now be diagnosed with a simple blood test. The study was published on December 1, 2014, in the Canadian Medical Association Journal.

Related Links:

University of Ottawa
Applied Biosystems


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more